Comparison of patients with ADAMTS13 activity < 10% at their initial diagnosis
| Clinical, demographic features . | Survival . | P . | Relapse . | P . | ||
|---|---|---|---|---|---|---|
| Survived (n = 47) . | Died (n = 13) . | Relapsed (n = 16) . | No relapse (n = 31) . | |||
| Age, y | 41 | 45 | .10 | 42 | 40 | .44 |
| Race, % black | 38 | 23 | .51 | 56 | 29 | .07 |
| Sex, % male | 19 | 15 | 1.00 | 38 | 10 | .05 |
| Severe neurologic abnormality, % | 47 | 62 | .35 | 50 | 45 | .75 |
| Hematocrit, % | 21 | 22 | .49 | 21 | 21 | .52 |
| Platelets, /μL | 11 | 10 | .96 | 11 | 10 | .80 |
| LDH, U/L | 1373 | 1776 | .82 | 1395 | 1373 | .80 |
| Creatinine, mg/dL | 1.2 | 2.9 | < .01 | 1.2 | 1.4 | .43 |
| ADAMTS13 inhibitor, % 2 or more BU | 30 | 62 | .05 | 13 | 39 | .09 |
| Plasma exchange, no. | 21 | 14 | .12 | |||
| Years of follow-up | 8.7 | 3.7 | < .01 | |||
| Clinical, demographic features . | Survival . | P . | Relapse . | P . | ||
|---|---|---|---|---|---|---|
| Survived (n = 47) . | Died (n = 13) . | Relapsed (n = 16) . | No relapse (n = 31) . | |||
| Age, y | 41 | 45 | .10 | 42 | 40 | .44 |
| Race, % black | 38 | 23 | .51 | 56 | 29 | .07 |
| Sex, % male | 19 | 15 | 1.00 | 38 | 10 | .05 |
| Severe neurologic abnormality, % | 47 | 62 | .35 | 50 | 45 | .75 |
| Hematocrit, % | 21 | 22 | .49 | 21 | 21 | .52 |
| Platelets, /μL | 11 | 10 | .96 | 11 | 10 | .80 |
| LDH, U/L | 1373 | 1776 | .82 | 1395 | 1373 | .80 |
| Creatinine, mg/dL | 1.2 | 2.9 | < .01 | 1.2 | 1.4 | .43 |
| ADAMTS13 inhibitor, % 2 or more BU | 30 | 62 | .05 | 13 | 39 | .09 |
| Plasma exchange, no. | 21 | 14 | .12 | |||
| Years of follow-up | 8.7 | 3.7 | < .01 | |||
Comparison of patients who survived to patients who died among the 60 patients with ADAMTS13 activity < 10% at the time of their initial diagnosis of TTP, and comparison of patients who relapsed to patients who did not relapse among the 47 survivors. Among 60 patients with ADAMTS13 activity < 10% at the time of their initial diagnosis, the 47 patients who survived are compared with the 13 patients who died. Among the 47 survivors, the 16 patients who have relapsed are compared with the 31 patients who have not relapsed. Continuous data are presented as median values. Severe neurologic abnormalities are defined as coma, stroke, seizure, or focal neurologic signs.9 Laboratory data are the most abnormal values at the time of diagnosis, defined as the day of the first plasma exchange treatment, ± 7 days to account for transient changes resulting from transfusion or worsening renal failure. LDH indicates lactate dehydrogenase; BU, Bethesda units/mL.